US Biosimilars Will Get Regulatory Science Program, Supplement Timeline Changes In Next User Fee Agreement

Talks are completed, leaving only the generic drug user fee reauthorization negotiations ongoing.

Sign outside of FDA's headquarters in White Oak, MD
The completed BsUFA III agreement includes supplement timeline improvements

US biosimilar user fee talks have ended with confirmation that a regulatory science program will be created, resolving an issue that emerged at the start of the talks about three months prior.

The FDA agreed to an industry counterproposal to allow biosimilar regulatory science research during a 25 May meeting, according to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products